Analyst Upgrades: Take-Two Interactive Software, Inc., Horizon Technology Finance Corp, and Lexicon Pharmaceuticals, Inc.

Analysts upwardly revised their ratings on Take-Two Interactive Software, Inc. (TTWO), Horizon Technology Finance Corp (HRZN), and Lexicon Pharmaceuticals, Inc. (LXRX)

by Josh Selway

Published on Nov 10, 2015 at 9:54 AM

Analysts are weighing in on video game maker Take-Two Interactive Software, Inc. (NASDAQ:TTWO), investment firm Horizon Technology Finance Corp (NASDAQ:HRZN), and biotech Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX). Here's a quick roundup of today's bullish brokerage notes on TTWO, HRZN, and LXRX.

  • Analysts continue to wax optimistic on TTWO, with Ascendiant Capital raising its price target to $42 from $37 -- in uncharted territory. Nevertheless, the stock is 0.3% lower at $32.88 this morning, but remains 17% higher year-to-date. Meanwhile, Take-Two Interactive Software, Inc.'s 50-day put/call volume ratio of 1.93 at the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) stands higher than 95% of all other readings from the past 12 months. This reveals a stronger-than-usual appetite for put buying over call buying of late. An unwinding of pessimism in the options pits could fuel TTWO even higher.
  • HRZN is up 2.4% at $11.12, after Raymond James raised its opinion to "outperform" from "market perform." This is a change of pace for the shares, as just two out of six covering analysts offer up "buy" or better ratings. Horizon Technology Finance Corp has shot higher during the past few sessions, and now sits in overbought territory, according to its 14-day Relative Strength Index (RSI) of 74. What's more, the stock is set to end atop $11 for the first time since mid-August.
  • LXRX is still enjoying some upbeat analyst attention, following Friday's announcement of a collaboration with Sanofi SA (ADR) (NYSE:SNY). This morning, Wedbush chimed in, bumping its price target to $26 -- twice LXRX's current price of $13.14. Despite a 5% dip today, the stock has been on fire recently, outperforming the SPX by more than 25 percentage points over the past three months. One group of traders is likely kicking themselves, though. That is, short interest on Lexicon Pharmaceuticals, Inc. surged by over 48% during the two most recent reporting periods, and now represents 13 days' worth of buying power, at the stock's normal trading volume. 
Get the skinny on all the biggest stories of the morning… Sign up now to get Schaeffer's Midday Market Check delivered straight to your inbox!

A Schaeffer's exclusive

TOP STOCK PICKS 2020

Access your FREE insider report before it's too late!


 
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


IRA/401k: The Crash-Proof Retirement Plan
Use gold to protect any IRA, 401(k), or retirement account from a looming financial crisis.
Software Stock Could Have Room to Run
The cloud stock could revisit record highs soon
Ulta Stock Moves Lower on New Coronavirus Measures
Ulta has closed all of its stores until further notice
IRA/401k: The Crash-Proof Retirement Plan
Use gold to protect any IRA, 401(k), or retirement account from a looming financial crisis.